We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+5.7%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.14B
AUM Growth
-$69.7M
Cap. Flow
-$57.8M
Cap. Flow %
-5.05%
Top 10 Hldgs %
63.1%
Holding
46
New
5
Increased
8
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$31.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$8.97M
3
SAGE
Sage Therapeutics
SAGE
+$4.48M
4
SANA icon
Sana Biotechnology
SANA
+$4.32M
5
VERV
Verve Therapeutics
VERV
+$4M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$25M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$18.7M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLFS icon
1
BioLife Solutions
BLFS
$1.56B
$171M 14.91%
7,721,535
+150,000
+2% +$3.16M
SRPT icon
2
Sarepta Therapeutics
SRPT
$1.63B
$116M 10.16%
1,015,000
-145,000
-13% -$18.7M
RLAY icon
3
Relay Therapeutics
RLAY
$4.04B
$75.3M 6.58%
5,998,574
+300,000
+5% +$3.73M
EQRX
4
DELISTED
EQRx, Inc. Common Stock
EQRX
$73.5M 6.43%
39,527,669
– –
ALNY icon
5
Alnylam Pharmaceuticals
ALNY
$29.1B
$53.2M 4.65%
280,000
+10,000
+4% +$1.98M
NTLA icon
6
Intellia Therapeutics
NTLA
$1.5B
$52M 4.54%
1,275,000
– –
RVMD icon
7
Revolution Medicines
RVMD
$38.8B
$48.4M 4.23%
1,810,000
– –
EXAS
8
DELISTED
Exact Sciences
EXAS
$47M 4.1%
500,000
-65,000
-12% -$5.07M
VERV
9
DELISTED
Verve Therapeutics
VERV
$44.3M 3.87%
2,360,571
+240,000
+11% +$4M
GPCR icon
10
Structure Therapeutics
GPCR
$3.39B
$41.4M 3.62%
997,017
+320,000
+47% +$8.97M
BPMC
11
DELISTED
Blueprint Medicines
BPMC
$39.2M 3.42%
620,000
-50,000
-7% -$2.72M
DNLI icon
12
Denali Therapeutics
DNLI
$3.67B
$38.4M 3.35%
1,300,000
– –
TNYA icon
13
Tenaya Therapeutics
TNYA
$162M
$37.5M 3.27%
6,381,377
+302,517
+5% +$1.76M
CTLT
14
DELISTED
CATALENT, INC.
CTLT
$31.2M 2.73%
+720,000
New +$31.6M
PLRX icon
15
Pliant Therapeutics
PLRX
$64.4M
$30.8M 2.69%
1,700,000
+25,000
+1% +$592K
SLGC
16
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$29.1M 2.54%
12,604,275
– –
ILMN icon
17
Illumina
ILMN
$30.2B
$29.1M 2.54%
159,340
-123,360
-44% -$25M
MXCT icon
18
MaxCyte
MXCT
$116M
$21.6M 1.89%
4,715,000
-210,000
-4% -$965K
TSVT
19
DELISTED
2seventy bio
TSVT
$20.5M 1.79%
2,023,913
– –
FDMT icon
20
4D Molecular Therapeutics
FDMT
$524M
$19.3M 1.69%
1,070,000
– –
WGS icon
21
GeneDx Holdings
WGS
$1.98B
$18.4M 1.61%
3,095,511
+2
+0% +$16
BEAM icon
22
Beam Therapeutics
BEAM
$2.66B
$18.2M 1.59%
570,000
– –
ABCL icon
23
AbCellera Biologics
ABCL
$1.78B
$16.3M 1.42%
2,520,000
– –
IPSC icon
24
Century Therapeutics
IPSC
$355M
$10.1M 0.89%
3,206,380
– –
FATE icon
25
Fate Therapeutics
FATE
$294M
$9.76M 0.85%
2,050,000
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Casdin Capital held 46 positions worth $1.14B, down 5.7% from $1.21B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Casdin Capital withdrew a net $57.8M in Q2 2023, closing 5 positions and reducing 9 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Casdin Capital opened a new position in CATALENT, INC. worth $31.2M.

  • Casdin Capital's largest Q2 2023 buy was CATALENT, INC.: 720,000 shares worth $31.2M.
  • Casdin Capital added most to Structure Therapeutics in Q2 2023, an estimated $8.97M increase.
  • Casdin Capital's biggest Q2 2023 reduction was Illumina, cutting an estimated $25M.
  • Casdin Capital fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Casdin Capital's ten largest holdings make up 63% of its $1.14B portfolio in Q2 2023.
  • Casdin Capital opened 5 new positions and closed 5 in Q2 2023.
  • Casdin Capital's portfolio value fell 5.7% quarter-over-quarter to $1.14B.

Based on Casdin Capital's 13F filing for Q2 2023, filed 14 Aug 2023.